The TRT story after TRAVERSE 2023 — what changed and what your doctor is still missing.

For two decades the testosterone replacement conversation was haunted by a single question: does TRT raise cardiovascular risk? In 2023, the TRAVERSE trial answered it. Most clinicians still havent updated.

After Forty Feel Editorial · 9 min read · Updated May 2026

If you are a man between 40 and 60 and youve looked into testosterone replacement therapy in the last decade, youve almost certainly run into the same wall. The doctor reads your bloodwork, sees a total testosterone of 320 ng/dL, and says some version of youre in the normal range, lets not do anything. The conversation ends there. So does any honest discussion of how you actually feel — the morning fatigue, the recovery time after lifting, the loss of motivation that doesnt map cleanly to depression, the libido that quietly disappeared somewhere in your forties.

The reason that conversation ends is a 2010 paper that linked TRT to cardiovascular events. That paper has shaped a generation of clinical caution. It has also been substantially superseded.

What TRAVERSE actually showed

The TRAVERSE trial (published in the New England Journal of Medicine in 2023) randomized 5,246 men aged 45-80 with low testosterone and pre-existing cardiovascular disease or high risk for it. Half received transdermal testosterone gel; half received placebo. The trial ran for roughly two years.

The result: testosterone replacement did not increase the rate of major adverse cardiovascular events — heart attack, stroke, cardiovascular death. The hazard ratio was effectively 1.0. This is the data the field had been waiting on for ten years. It did not say TRT is risk-free (there were small increases in pulmonary embolism, atrial fibrillation, and acute kidney injury). But the headline cardiovascular question — the one that froze the field — got answered.

Who actually qualifies for the conversation

The Endocrine Society 2024 update is clear: testosterone replacement should be considered for men with consistent symptoms of hypogonadism plus unequivocally low morning total testosterone. The numerical threshold most clinicians use is below 264 ng/dL on two separate morning draws. Free testosterone matters more than total for many men — the assay is harder, but a free T below roughly 6.4 ng/dL with symptoms is a clinical conversation.

Symptoms that warrant the conversation: decreased libido, erectile dysfunction, fatigue not explained by sleep, depressed mood, loss of body hair, gynecomastia, decreased muscle mass, decreased bone density, infertility. The combination matters more than any single one — most 50-year-old men have some of these regardless of testosterone level.

The four modalities, ranked

If the conversation produces a yes:

• Transdermal gel (AndroGel, Testim, Fortesta) — daily application, smoothest pharmacokinetics, primary downside is transfer risk to partners and kids. Most clinicians start here.
• Intramuscular injection (testosterone cypionate, enanthate) — every 7-14 days self-administered, more predictable absorption, peaks-and-troughs in mood for some men. Costs 0-50/month.
• Subcutaneous injection — same hormones as IM but smaller needle, less pain, slightly different absorption curve. Gaining traction.
• Pellet implant — placed under skin every 3-4 months by clinician. Set-and-forget but harder to adjust dose if levels run high.

What an honest clinician conversation sounds like

Bring these to the appointment: two morning total T draws on different days, free T if available, complete blood count (for hematocrit baseline), PSA, estradiol, LH and FSH (to distinguish primary from secondary hypogonadism), comprehensive metabolic panel. If the clinician wont order them, find a different clinician.

The questions worth asking: What threshold are you using for total T? Do you trend free testosterone? How will you monitor hematocrit and PSA? What is your target range, and how do you adjust if I am over or under? Do you have experience treating men with normal-range total but symptomatic free T?

What TRT cannot fix

Testosterone replacement is not a productivity drug, not a longevity protocol with proven evidence, not a substitute for sleep / strength training / protein floor / alcohol moderation. Men whose lifestyle baseline is broken get smaller responses to TRT and larger side effects. The clinicians who get the best outcomes from TRT also coach their patients on the rest of the stack — sleep architecture, resistance training twice weekly, protein floor of 0.8-1.0 g per pound of lean mass, alcohol cap at 5-7 drinks per week.

Cognition improves in some men on TRT and not in others. Mood improves more reliably. Libido improvement is the most consistent. Strength gains are real but modest without training stimulus. Body composition shifts (more lean mass, less visceral fat) take 6-12 months and require concurrent training.

The honest caveats

TRT increases hematocrit; you may need to donate blood every 8-12 weeks to stay safe. Fertility drops sharply — exogenous testosterone shuts down endogenous production and sperm count. If you want children, talk about hCG or clomiphene before starting. Long-term cardiovascular safety past 5 years is still under study. Cost ranges from 0/month (generic IM) to 00+/month (branded gels or pellets) depending on insurance.

And: TRT is for life if you start. The honest framing is not should I try testosterone, it is am I prepared to be on testosterone forever.